Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis inducing damage of the aorta and its branches. Glucocorticoids remain the gold standard of therapy in TA. However, the nature of T cell driving vascular inflammation and the effects of glucocorticoids on the systemic components of TA are not understood.
Methods: T cell homeostasis and cytokines production were analyzed in peripheral blood and aorta inflammatory lesions using Luminex, flow cytometry, and immunohistochemistry analysis. The study included 41 TA patients fulfilling the ACR criteria [17 active (aTA) and 24 in remission (rTA)], 30 giant cell arteritis (GCA) patients (disease control) and 20 age and sex-matched controls.
Results:
We first demonstrated the promotion of Th1 and Th17 responses that correlates with TA activity. We determined whether serum from TA patients was able to modulate T cell differentiation in healthy controls. The addition of serum from active TA patients in sorted CD4+ T cells culture of healthy donors induced a significant production of IFN-g and IL-17A. We demonstrated the the strong expression of IFN-g, and IL-6 producing T cells within vascular inflammatory infiltrates of TA. Glucocorticoid therapy were associated to decreased circulating Th1 cytokines with significantly lower IL-2 (mean±SEM; 2812±690.1 vs. 7228±1536 pg/ml, p=0.0196), IFN-g (1437±367.3 vs. 7124±1818pg/ml, p=0.0019) and TNF-a (643.3±106.4 vs. 1438±196.6pg/ml, p=0.01) in steroid treated TA compared to steroid free TA patients, respectively. However, glucocorticoids essentially left unaffected Th17 cytokines (i.e. IL-1b, IL-6, IL-17 and IL-23).
Conclusion: Our data provided the first evidence that Th1 and Th17 immunity seems to be important in driving TA inflammation, both systemically and in the blood vessels. In addition, only one of these pathways was amendable to glucocorticoid-mediated suppression. Glucocorticoids are associated to decrease Th1 cytokines and spared Th17 cytokines in TA.
Disclosure:
D. Saadoun,
None;
M. Garrido,
None;
C. Comarmond,
None;
A. C. Desbois,
None;
F. Domont,
None;
L. Savey,
None;
B. Terrier,
None;
M. Rosenzwajg,
None;
D. Klatzman,
None;
P. Fourret,
None;
P. Cluzel,
None;
L. Chiche,
None;
J. Gaudric,
None;
F. Koskas,
None;
P. Cacoub,
Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier, Vifor.,
5.
« Back to 2014 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/th1-and-th17-cytokines-drive-takayasu-arteritis-inflammation/